BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...held 7.5%.Goldman Sachs & Co. LLC, Jefferies, Stifel and JMP Securities are Athira's underwriters. Cowen, Evercore ISI...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...shared on a conference call Monday by Evercore ISI...
BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...on Change in IPO Plans”).Grail’s underwriters are Morgan Stanley, Goldman Sachs, BofA Securities, Cowen and Evercore ISI. Paul...
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...the role on an interim basis while the regenerative medicines company searches for a successor.Research firm Evercore ISI...
...company in 2017 as director of operations. Robin Sawka Kymera Therapeutics Inc. Immunovia AB Apic Bio Inc. Vor Biopharma Inc. Organogenesis Inc. Evercore ISI Saniona...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...gained 58% in its first day, and closed Friday at $26.94. Nkarta’s underwriters were Cowen, Evercore ISI...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...Prevnar 13 or its successors from Pfizer Inc. (NYSE:PFE). Its underwriters are BofA Securities, Jefferies, Evercore ISI...
...elexacaftor/tezacaftor/ivacaftor. Royalty Pharma's underwriters are J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup, UBS, Evercore ISI...
BioCentury | Apr 23, 2020
Product Development

First glimpse of controlled remdesivir data cast doubt on its COVID-19 treatment potential

...in disease.” The potential for early treatment benefit was also highlighted in a note from Evercore ISI’s...
BioCentury | Apr 23, 2020
Finance

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

...this stage (see “Biogen Presses Ahead with Aducanumab Plans” ). In an analyst note Wednesday, Evercore ISI’s...
BioCentury | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

...first nine months of 2019; it does not break out PNH sales for the drugs. Evercore ISI...
...the sale of 7 million shares in a follow-on underwritten by Citigroup, J.P. Morgan and Evercore ISI...
BioCentury | Dec 31, 2019
Politics & Policy

China’s expanded list of drugs for centralized procurement comes with new rules

...affect the market dominance of Viagra sildenafil from Pfizer’s Upjohn unit for ED, according to Evercore ISI...
Items per page:
1 - 10 of 89
BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...held 7.5%.Goldman Sachs & Co. LLC, Jefferies, Stifel and JMP Securities are Athira's underwriters. Cowen, Evercore ISI...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...shared on a conference call Monday by Evercore ISI...
BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...on Change in IPO Plans”).Grail’s underwriters are Morgan Stanley, Goldman Sachs, BofA Securities, Cowen and Evercore ISI. Paul...
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...the role on an interim basis while the regenerative medicines company searches for a successor.Research firm Evercore ISI...
...company in 2017 as director of operations. Robin Sawka Kymera Therapeutics Inc. Immunovia AB Apic Bio Inc. Vor Biopharma Inc. Organogenesis Inc. Evercore ISI Saniona...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...gained 58% in its first day, and closed Friday at $26.94. Nkarta’s underwriters were Cowen, Evercore ISI...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...Prevnar 13 or its successors from Pfizer Inc. (NYSE:PFE). Its underwriters are BofA Securities, Jefferies, Evercore ISI...
...elexacaftor/tezacaftor/ivacaftor. Royalty Pharma's underwriters are J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup, UBS, Evercore ISI...
BioCentury | Apr 23, 2020
Product Development

First glimpse of controlled remdesivir data cast doubt on its COVID-19 treatment potential

...in disease.” The potential for early treatment benefit was also highlighted in a note from Evercore ISI’s...
BioCentury | Apr 23, 2020
Finance

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

...this stage (see “Biogen Presses Ahead with Aducanumab Plans” ). In an analyst note Wednesday, Evercore ISI’s...
BioCentury | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

...first nine months of 2019; it does not break out PNH sales for the drugs. Evercore ISI...
...the sale of 7 million shares in a follow-on underwritten by Citigroup, J.P. Morgan and Evercore ISI...
BioCentury | Dec 31, 2019
Politics & Policy

China’s expanded list of drugs for centralized procurement comes with new rules

...affect the market dominance of Viagra sildenafil from Pfizer’s Upjohn unit for ED, according to Evercore ISI...
Items per page:
1 - 10 of 89